RLYB Rallybio Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: RLYB

Price (delayed)

$16.15

Market cap

$85.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.37

Enterprise value

$44.42M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 44
Highlights
The EPS has soared by 84% year-on-year and by 14% since the previous quarter
Rallybio's net income has surged by 84% YoY and by 13% QoQ
RLYB's debt is up by 33% year-on-year but it is down by 13% since the previous quarter
The quick ratio has contracted by 19% YoY and by 13% from the previous quarter
The equity has declined by 13% since the previous quarter and by 7% year-on-year
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RLYB

RLYB stock price

How has the Rallybio stock price performed over time
Intraday
0.5%
1 week
11.23%
1 month
14.38%
1 year
436.54%
YTD
194.17%
QTD
80.04%

Financial performance

How have Rallybio's revenue and profit performed over time
Revenue
$858,000
Gross profit
$858,000
Operating income
-$32.13M
Net income
-$7.82M
Gross margin
100%
Net margin
-911.1%
RLYB's net margin has soared by 84% year-on-year and by 13% since the previous quarter
Rallybio's net income has surged by 84% YoY and by 13% QoQ
Rallybio's operating margin has increased by 37% YoY and by 2.8% from the previous quarter
RLYB's operating income is up by 36% year-on-year and by 2.8% since the previous quarter

Price vs fundamentals

How does RLYB's price correlate with its fundamentals

Growth

What is Rallybio's growth rate over time

Valuation

What is Rallybio stock price valuation
P/E
N/A
P/B
1.7
P/S
107.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
51.77
The EPS has soared by 84% year-on-year and by 14% since the previous quarter
RLYB's price to book (P/B) is 41% higher than its 5-year quarterly average of 1.2
The equity has declined by 13% since the previous quarter and by 7% year-on-year
The stock's price to sales (P/S) is 186% more than its last 4 quarters average of 37.2

Efficiency

How efficient is Rallybio business performance
The ROS has soared by 84% year-on-year and by 13% since the previous quarter
RLYB's return on equity has surged by 80% year-on-year and by 11% since the previous quarter
Rallybio's return on assets has surged by 79% YoY and by 11% QoQ
The ROIC has soared by 69% year-on-year but it has declined by 12% since the previous quarter

Dividends

What is RLYB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLYB.

Financial health

How did Rallybio financials performed over time
The quick ratio has contracted by 19% YoY and by 13% from the previous quarter
The total assets has declined by 13% since the previous quarter and by 6% year-on-year
RLYB's debt is 100% smaller than its equity
RLYB's debt is up by 33% year-on-year but it is down by 13% since the previous quarter
The equity has declined by 13% since the previous quarter and by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.